KR20070031281A - How to make A4N - Google Patents
How to make A4N Download PDFInfo
- Publication number
- KR20070031281A KR20070031281A KR1020067018670A KR20067018670A KR20070031281A KR 20070031281 A KR20070031281 A KR 20070031281A KR 1020067018670 A KR1020067018670 A KR 1020067018670A KR 20067018670 A KR20067018670 A KR 20067018670A KR 20070031281 A KR20070031281 A KR 20070031281A
- Authority
- KR
- South Korea
- Prior art keywords
- aq4n
- acid
- reaction
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000006243 chemical reaction Methods 0.000 claims abstract description 54
- YZBAXVICWUUHGG-UHFFFAOYSA-N 2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-n,n-dimethylethanamine oxide Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCC[N+](C)(C)[O-])=CC=C2NCC[N+](C)([O-])C YZBAXVICWUUHGG-UHFFFAOYSA-N 0.000 claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 239000007800 oxidant agent Substances 0.000 claims abstract description 13
- 239000012453 solvate Substances 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 230000001590 oxidative effect Effects 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- USSBDBZGEDUBHE-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate Chemical group [Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O USSBDBZGEDUBHE-UHFFFAOYSA-L 0.000 claims description 8
- 150000004965 peroxy acids Chemical group 0.000 claims description 8
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 7
- 239000002738 chelating agent Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 7
- 235000013772 propylene glycol Nutrition 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical group O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000012267 brine Substances 0.000 claims description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- 229910052782 aluminium Inorganic materials 0.000 description 10
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- -1 oxy anthracene Chemical compound 0.000 description 8
- 239000006227 byproduct Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 239000011877 solvent mixture Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 0 *C1(ON1*)F Chemical compound *C1(ON1*)F 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- MPBKAOHKPAKJDA-VCHYOVAHSA-N 2-(3-aminopropyl)-1-[(e)-(2,2-difluoro-1-phenylethylidene)amino]guanidine Chemical compound NCCCN=C(N)N\N=C(\C(F)F)C1=CC=CC=C1 MPBKAOHKPAKJDA-VCHYOVAHSA-N 0.000 description 2
- MKHGVMIXRPGHOO-UHFFFAOYSA-N 2-(benzenesulfonyl)-3-phenyloxaziridine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1OC1C1=CC=CC=C1 MKHGVMIXRPGHOO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical group CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002891 organic anions Chemical class 0.000 description 2
- SJGALSBBFTYSBA-UHFFFAOYSA-N oxaziridine Chemical compound C1NO1 SJGALSBBFTYSBA-UHFFFAOYSA-N 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- QVLAWKAXOMEXPM-UHFFFAOYSA-N 1,1,1,2-tetrachloroethane Chemical compound ClCC(Cl)(Cl)Cl QVLAWKAXOMEXPM-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LZBASGXGFUSJLV-UHFFFAOYSA-N 1-amino-4-[2-(dimethylamino)ethylamino]-5,8-dihydroxyanthracene-9,10-dione Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(N)=CC=C2NCCN(C)C LZBASGXGFUSJLV-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- SBWCPHUXRZRTDP-UHFFFAOYSA-N 2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-n,n-dimethylethanamine oxide;dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCC[N+](C)(C)[O-])=CC=C2NCC[N+](C)([O-])C SBWCPHUXRZRTDP-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- AVLRPSLTCCWJKC-UHFFFAOYSA-N 4,7-difluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C(F)C2=C1C(=O)OC2=O AVLRPSLTCCWJKC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- NELACHBDCVNKTB-UHFFFAOYSA-N C(CC1)CCC11ON1 Chemical compound C(CC1)CCC11ON1 NELACHBDCVNKTB-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000004843 oxaziridines Chemical class 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SPDUKHLMYVCLOA-UHFFFAOYSA-M sodium;ethaneperoxoate Chemical compound [Na+].CC(=O)O[O-] SPDUKHLMYVCLOA-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
- C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
- C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
- C07C225/34—Amino anthraquinones
- C07C225/36—Amino anthraquinones the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
- C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
- C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
화학식 (2)의 화합물 AQ4N 또는 그 염 또는 용매화물의 제조방법에 있어서, 화학식 (1)의 화합물 AQ4를 10℃를 넘지 않는 반응 온도에서 산화제로 화학식 (2)의 화합물 AQ4N으로 산화시키는 반응 단계를 포함하는 제조방법.In the process for preparing compound AQ4N of formula (2) or a salt or solvate thereof, the reaction step of oxidizing compound AQ4 of formula (1) to compound AQ4N of formula (2) with an oxidizing agent at a reaction temperature not exceeding 10 ° C. Manufacturing method comprising.
AQ4N, AQ4AQ4N, AQ4
Description
본 발명은 AQ4N, 그리고 그 염 및 용매화물의 제조방법에 관한 것이다. 특히, 본 방법은 공업적 규모로 이용할 수 있으며 약학적으로 순수한 화합물의 제조에 적합하다.The present invention relates to AQ4N, and to a process for preparing the salts and solvates thereof. In particular, the method is available on an industrial scale and is suitable for the preparation of pharmaceutically pure compounds.
AQ4N은 암 치료에 유용한 비독성 전구약물(prodrug)이다. 활성 약물은 세포독성 화합물 AQ4로서, 이는 저산소 세포에서 환원 대사에 의해 AQ4N으로부터 생체 내(in vivo) 생성된다. 이 과정은 AQ4로부터 AQ4N을 합성하는 데 이용되는 산화 단계의 역반응이다.AQ4N is a non-toxic prodrug useful for the treatment of cancer. The active drug is the cytotoxic compound AQ4, which is produced in vivo from AQ4N by reductive metabolism in hypoxic cells. This process is the reverse reaction of the oxidation step used to synthesize AQ4N from AQ4.
AQ4N의 대응 용매화물 또는 염, 예컨대 약학적으로 허용가능한 염을 제조, 정제, 및/또는 취급하는 것이 종종 편리하거나 바람직하다. 약학적으로 허용가능한 염의 예는 Berge et al, 1977, "Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1-19에 논의되어 있다. AQ4N은 많은 염 또는 용매화물의 형태 로 보고되어 왔다 (J. Chem. Soc., Perkin Trans. I, 1999, 2755; WO 00/05194; WO 03/078387).It is often convenient or desirable to prepare, purify, and / or handle the corresponding solvates or salts of AQ4N, such as pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts are described in Berge et al, 1977, "Pharmaceutically Acceptable Salts," J. Pharm. Sci. , Vol. 66, pp. Discussed in 1-19. AQ4N has been reported in the form of many salts or solvates ( J. Chem. Soc., Perkin Trans. I , 1999, 2755; WO 00/05194; WO 03/078387).
그러나, AQ4N 및 그 염 또는 용매화물의 공지된 제조방법의 문제점은 생성 결과물이 AQMN으로 알려진 불순물을 다양한 정도로 함유한다는 점이다. AQMN 또는 1-아미노-4-{[2-(다이메틸아미노)에틸]아미노}-5,8-다이하이드록시안트라퀴논은 AQ4N의 분해에 의해 형성된다. AQMN은 비독성 전구약물로서 투여되는 것을 목적으로 하는 화합물에서 바람직하지 못한 오염물이다.However, a problem with known methods of preparing AQ4N and its salts or solvates is that the resulting product contains varying degrees of impurities known as AQMN. AQMN or 1-amino-4-{[2- (dimethylamino) ethyl] amino} -5,8-dihydroxyanthraquinone is formed by the decomposition of AQ4N. AQMN is an undesirable contaminant in compounds intended to be administered as nontoxic prodrugs.
AQ4N 그리고 그 염 또는 용매화물은 WO 00/05194 및 하기에 설명한 바와 같이 몇 단계의 반응을 채용한 공정을 이용하여 제조할 수 있다. 이 방법은 소규모 (~0.1몰) 로 수행되었다. 이 공정의 한 단계는 염화 알루미늄 촉매를 이용한 프리델-크라프트 아실화에 의한 3,6-다이플루오로 무수프탈산(DFPA) 및 p-하이드로퀴논의 1,4-다이플루오로-5,8-다이하이드록시 안트라센(DDA)으로의 변환이다.AQ4N and its salts or solvates can be prepared using a process employing several steps of reactions as described in WO 00/05194 and below. This method was performed on a small scale (~ 0.1 moles). One step of this process is 1,4-difluoro-5,8-dihydride of 3,6-difluorophthalic anhydride (DFPA) and p-hydroquinone by Friedel-Craft acylation with an aluminum chloride catalyst. Conversion to oxy anthracene (DDA).
이 반응은 고체 (4), (5), 염화 소듐 및 삼염화 알루미늄의 분말 혼합물을 220℃의 온도로 가열하여 수행하였다.This reaction was carried out by heating a powder mixture of solids (4), (5), sodium chloride and aluminum trichloride to a temperature of 220 ° C.
다음으로, DDA의 불소 원자를 다음 반응과 같이 N,N-다이메틸에틸렌다이아민으로 치환하여 AQ4를 생성한다.Next, the fluorine atom of DDA is substituted with N, N-dimethylethylenediamine to produce AQ4 as in the following reaction.
WO 00/05194에 설명된 방법에서, 이 반응 단계는 약 0.1몰의 실험실 크기의 규모에서도 중간 정도의 생성물 수율(~40%)만을 나타내었다.In the process described in WO 00/05194, this reaction step showed only moderate product yield (-40%), even on a laboratory size scale of about 0.1 mole.
다음으로, 후속 반응 단계를 수행하여 AQ4를 AQ4N으로 산화한다.Next, a subsequent reaction step is performed to oxidize AQ4 to AQ4N.
WO 00/05194에 설명된 방법은 데이비스 시약(2-벤젠-설포닐-3-페닐-옥사지리딘)을 산화제로 이용하고, 반응은 실온에서 수행한다.The process described in WO 00/05194 uses Davis reagent (2-benzene-sulfonyl-3-phenyl-oxaziridine) as oxidant and the reaction is carried out at room temperature.
이 시점에서 AQ4N을 분리하거나, 추가 반응 단계에서 이를 염 또는 용매화물로 추가 변환시킬 수 있다. AQ4N 조생성물의 메탄올 용액을 실온에서 무수 HCl 기체로 처리하여 무기 이염산염을 실험실 규모로 제조하였다 (WO 00/05194). AQ4N의 유기산 염 또한 유기산을 함유하는 메탄올 용액을 첨가함으로써 제조하였다 (WO 03/078387).At this point AQ4N can be separated off or further converted to salts or solvates in further reaction steps. Inorganic dihydrochloride was prepared on a laboratory scale by treating the methanol solution of the AQ4N crude product with anhydrous HCl gas at room temperature (WO 00/05194). Organic acid salts of AQ4N were also prepared by adding a methanol solution containing organic acid (WO 03/078387).
발명의 개시Disclosure of the Invention
본 발명은 AQ4N 및 그 염 또는 용매화물의 개선된 제조방법을 개시한다. 본 방법은 공업적 규모(예컨대, 최소 0.2mol)로 수행할 수 있으며 중간체 화합물의 개선된 합성방법을 포함한다. 이들 개선된 방법은 약학적으로 순수할 수 있는 최종 생성물 내의 감소한 수준의 오염물을 생성하는 것을 목적으로 한다. 본 발명의 방법은 상기 설명한 반응 순서 및 중간체를 일반적으로 이용한다.The present invention discloses an improved process for preparing AQ4N and salts or solvates thereof. The process can be carried out on an industrial scale (eg, at least 0.2 mol) and includes improved methods of synthesizing intermediate compounds. These improved methods aim to produce reduced levels of contaminants in the final product that can be pharmaceutically pure. The process of the invention generally utilizes the reaction sequences and intermediates described above.
AQ4의 AQ4N으로의 산화Oxidation of AQ4 to AQ4N
AQ4의 AQ4N으로의 변환에서의 문제점은 AQ4의 불완전한 산화가 부분적으로 산화된 부생성물 AQ4M(7)의 생성으로 이어질 수 있다는 점이다. 그러나, 완전한 산화를 보장하기 위해 채용하는 격한 조건은 AQ4N의 AQMN으로의 분해를 종종 낳는다. 분해물 AQMN은 상대적으로 온건한 조건하에서도 얻어진다 (WO 03/078387). 이 분해 경로는 최종 생성물의 수율 및 순도 모두를 감소시킨다.The problem with the conversion of AQ4 to AQ4N is that incomplete oxidation of AQ4 can lead to the production of partially oxidized byproduct AQ4M (7). However, the harsh conditions employed to ensure complete oxidation often result in the degradation of AQ4N to AQMN. Degradate AQMN is obtained even under relatively moderate conditions (WO 03/078387). This degradation route reduces both the yield and purity of the final product.
본 발명의 한 양태는 AQ4의 AQ4N으로의 산화를 10℃를 넘지 않는 온도에서 수행하는 것이다. 반응 온도는 바람직하게는 5℃ 미만, 보다 바람직하게는 0℃ 미만이고, 가능하다면 반응 온도는 -7℃를 넘지 않는다. 반응은 보통 -20℃보다 높은 온도에서 수행한다. 반응 용액이 0℃를 넘지 않는, 보다 바람직하게는 -7℃ 미만의 온도일 때, 더욱 더 바람직하게는 반응 용액 온도가 -10℃를 넘지 않을 때 반응 혼합물에의 산화제 첨가를 수행한다. 반응 온도에 적절한 용매를 선택하여야 한다.One aspect of the invention is the oxidation of AQ4 to AQ4N at temperatures not exceeding 10 ° C. The reaction temperature is preferably below 5 ° C., more preferably below 0 ° C., and if possible the reaction temperature does not exceed −7 ° C. The reaction is usually carried out at temperatures higher than -20 ° C. When the reaction solution is at a temperature not exceeding 0 ° C., more preferably below −7 ° C., even more preferably, the addition of an oxidant to the reaction mixture is carried out when the reaction solution temperature does not exceed −10 ° C. A solvent suitable for the reaction temperature should be selected.
AQ4를 AQ4N으로 선택적으로 산화하는 산화제를 본 발명의 이 양태에서 바람직하게 이용한다. 적절한 산화제는 과산화수소, 옥사지리딘 또는 과산(peracid) 또는 과산의 염을 포함하며, 예컨대 m-클로로과벤조산, 과벤조산, 과아세트산 및 마그네슘 모노퍼옥시프탈레이트이다. 산화제는 바람직하게는 과산화수소 또는 보다 바람직하게는 마그네슘 모노퍼옥시프탈레이트이다. 산화제 마그네슘 모노퍼옥시프탈레이트는 공기중에서 안정하고 수용성이어서, 대규모 이용시에 보다 취급이 수월하다. 이용하는 용매는 선택한 산화제와 적합성이어야 한다.An oxidant which selectively oxidizes AQ4 to AQ4N is preferably used in this embodiment of the present invention. Suitable oxidizing agents include hydrogen peroxide, oxaziridine or peracids or salts of peracids, such as m-chloroperbenzoic acid, perbenzoic acid, peracetic acid and magnesium monoperoxyphthalate. The oxidant is preferably hydrogen peroxide or more preferably magnesium monoperoxyphthalate. The oxidizing agent magnesium monoperoxyphthalate is stable and water soluble in air, making it easier to handle in large scale use. The solvent used must be compatible with the oxidant selected.
AQ4의 AQ4N으로의 산화에 적절한 용매는 다이클로로메탄, 클로로폼, 다이클로로에탄, 사염화탄소, 톨루엔, 1,2-프로판다이올 또는 이들 용매의 임의의 조합의 용매 혼합물을 포함한다. 이들 모든 용매는 지방족 알킬 알콜이 있거나 없는 혼합물로서 이용할 수도 있다. 반응 용매는 바람직하게는 1,2-프로판다이올 또는 보다 바람직하게는 다이클로로메탄과 지방족 알킬 알콜의 용매 혼합이다.Suitable solvents for the oxidation of AQ4 to AQ4N include solvent mixtures of dichloromethane, chloroform, dichloroethane, carbon tetrachloride, toluene, 1,2-propanediol or any combination of these solvents. All these solvents may be used as mixtures with or without aliphatic alkyl alcohols. The reaction solvent is preferably 1,2-propanediol or more preferably a solvent mixture of dichloromethane and aliphatic alkyl alcohol.
따라서, 바람직한 구체예는 마그네슘 모노퍼옥시프탈레이트를 이용한다. 마그네슘 모노퍼옥시프탈레이트의 첨가는 -15℃ 내지 -5℃, 보다 바람직하게는 약 -11℃의 온도에서 수행한다. 산화제의 첨가 뒤, 반응을 -15℃ 내지 5℃, 보다 바람직하게는 약 0℃의 온도에서 교반되도록 한다. 이 반응에 바람직한 용매는 메탄올과 다이클로로메탄의 혼합물이며, 바람직하게는 1:1.5 내지 1:2.5의 부피비이다.Thus, a preferred embodiment uses magnesium monoperoxyphthalate. The addition of magnesium monoperoxyphthalate is carried out at temperatures of -15 ° C to -5 ° C, more preferably about -11 ° C. After addition of the oxidizing agent, the reaction is allowed to stir at a temperature of -15 ° C to 5 ° C, more preferably about 0 ° C. Preferred solvents for this reaction are mixtures of methanol and dichloromethane, preferably in a volume ratio of 1: 1.5 to 1: 2.5.
AQ4N의 염 형성Salt Formation of AQ4N
기존 방법에서, AQ4N의 이염산염은 AQ4N 용액을 무수 HCl 기체와 반응시켜 제조하였다 (WO 00/05194). HCl 기체 시약의 이용은 이 반응 단계의 규모 상승을 어렵게 한다. AQ4N의 염이 필요하다면, AQ4N의 용액을 용매 내 용해된 산과 반응시켜 제조할 수 있다. AQ4N의 산과의 반응은 바람직하게는 -20℃ 내지 -11℃의 온도에서 수행한다. 산은 용매에 용해시켜 반응에 첨가할 수 있거나, 적절한 시약의 첨가에 의해 반응 용액에서 현장(in-situ) 생성할 수 있다. 예컨대, 염산은 염화 아세틸과 에탄올 시약을 반응 용액에 첨가하여 현장 생성할 수 있다.In conventional methods, dihydrochloride of AQ4N was prepared by reacting an AQ4N solution with anhydrous HCl gas (WO 00/05194). The use of HCl gas reagents makes it difficult to scale up this reaction step. If a salt of AQ4N is needed, it can be prepared by reacting a solution of AQ4N with an acid dissolved in a solvent. The reaction of AQ4N with acid is preferably carried out at temperatures of -20 ° C to -11 ° C. The acid can be dissolved in a solvent and added to the reaction, or can be generated in-situ in the reaction solution by the addition of appropriate reagents. For example, hydrochloric acid can be produced in situ by adding acetyl chloride and ethanol reagent to the reaction solution.
적합한 무기산은 염산, 브롬산, 인산 및 황산을 포함한다. 적합한 유기산은 아세트산, 이염화아세트산, 말론산, 말레산, 타르타르산, 피멜산, 젖산, 구연산 및 벤젠설폰산을 포함한다.Suitable inorganic acids include hydrochloric acid, bromic acid, phosphoric acid and sulfuric acid. Suitable organic acids include acetic acid, dichloroacetic acid, malonic acid, maleic acid, tartaric acid, pimelic acid, lactic acid, citric acid and benzenesulfonic acid.
AQ4N의 염 형성에 적합한 용매는 다이클로로메탄, 클로로폼, 다이클로로에탄, 사염화탄소, 톨루엔, 1,2-프로판다이올 또는 이들 용매의 임의의 조합의 용매 혼합물을 포함한다. 이들 모든 용매는 지방족 알킬 알콜이 있거나 없는 혼합물로서 이용할 수도 있다. 반응 용매는 바람직하게는 1,2-프로판다이올 또는 보다 바람직하게는 다이클로로메탄과 지방족 알킬 알콜의 용매 혼합이다.Suitable solvents for salt formation of AQ4N include solvent mixtures of dichloromethane, chloroform, dichloroethane, carbon tetrachloride, toluene, 1,2-propanediol or any combination of these solvents. All these solvents may be used as mixtures with or without aliphatic alkyl alcohols. The reaction solvent is preferably 1,2-propanediol or more preferably a solvent mixture of dichloromethane and aliphatic alkyl alcohol.
AQ4N 또는 그 염의 정제Purification of AQ4N or its salts
기존 문헌의 방법들은 AQ4N의 염으로부터 주요 불순물을 제거하는 데 효과적이지 못했다. 본 발명의 또 하나의 양태에서, AQ4N 또는 AQ4N의 염과 관계된 정제 단계들 가운데 하나는 이 화합물의 용액을 활성탄(activated charcoal)을 통해 통과시키는 것임이 바람직하다. 이는 유색 화합물의 이례적인 정제방법인데, 왜냐하면 숯처리는 유색 불순물의 제거방법으로 본 기술분야에 주지되어 있기 때문이다. 이 단계로부터 얻는 최종 생성물은 J. Chem. Soc., Perkin Trans. I, 1999, 2755에 설명된 방법과 같이 재결정할 필요가 없다.The existing literature methods have not been effective in removing major impurities from the salts of AQ4N. In another embodiment of the present invention, it is preferred that one of the purification steps associated with AQ4N or a salt of AQ4N is to pass a solution of this compound through activated charcoal. This is an unusual method of purifying colored compounds because charcoal treatment is well known in the art as a method of removing colored impurities. The final product obtained from this step is J. Chem. Soc., Perkin Trans. There is no need to recrystallize as described in I , 1999, 2755.
이 단계에 적합한 용매는 다이클로로메탄, 클로로폼, 다이클로로에탄, 사염화탄소, 톨루엔, 1,2-프로판다이올 또는 이들 용매의 임의의 조합의 용매 혼합물을 포함한다. 이들 모든 용매는 지방족 알킬 알콜이 있거나 없는 혼합물로서 이용할 수도 있다. 반응 용매는 바람직하게는 1,2-프로판다이올 또는 보다 바람직하게는 다이클로로메탄과 지방족 알킬 알콜의 용매 혼합이다. 전형적으로, 정제할 화합물은 그것이 생성된 용매 내에 있다.Suitable solvents for this step include solvent mixtures of dichloromethane, chloroform, dichloroethane, carbon tetrachloride, toluene, 1,2-propanediol or any combination of these solvents. All these solvents may be used as mixtures with or without aliphatic alkyl alcohols. The reaction solvent is preferably 1,2-propanediol or more preferably a solvent mixture of dichloromethane and aliphatic alkyl alcohol. Typically, the compound to be purified is in the solvent from which it is produced.
프리델-크라프트 아실화Friedel-Craft Acylation
p-하이드로퀴논의 프리델-크라프트 아실화는 WO 00/05194에서 220℃에서의 고체 시약간의 반응에 의해 수행하였다. 고온 및 고상 반응 조건은 이 단계를 공업적 규모로 수행하기 어렵게 만든다. 다량의 기체가 이 반응 단계 도중 발생한다.Friedel-Craft acylation of p-hydroquinone was carried out by reaction between solid reagents at 220 ° C. in WO 00/05194. High temperature and solid phase reaction conditions make this step difficult to perform on an industrial scale. Large amounts of gas are generated during this reaction step.
본 발명의 또 하나의 양태는 이 반응 단계를 200℃를 넘지 않는 온도에서 용매에서 수행하는 것이다. 용매의 이용은 반응이 교반될 수 있도록 하고, 이는 다시 낮은 반응 온도를 이용할 수 있다는 것을 의미한다. 낮은 온도는 반응으로부터의 기체 발생 속도를 감소시킨다.Another aspect of the invention is to carry out this reaction step in a solvent at a temperature not exceeding 200 ° C. The use of a solvent allows the reaction to be stirred, which in turn means that a lower reaction temperature can be used. Lower temperatures reduce the rate of gas evolution from the reaction.
p-하이드로퀴논의 프리델-크라프트 아실화에 이용하는 적합한 용매는 1,1,1,2-테트라클로로에탄, 1,1,2,2-테트라클로로에탄, 나이트로벤젠, 클로로벤젠, 1,2-다이클로로벤젠, 톨루엔 또는 설폰이다. 이들 용매는 독립적으로 또는 다른 것과의 임의의 조합으로 이용할 수 있다. 설폰은 바람직하게는 테트라메틸렌 설폰이다. 반응은 반응 혼합물의 교반과 함께 180℃를 넘지 않는 온도에서 바람직하게 수행한다.Suitable solvents for the Friedel-Craft acylation of p-hydroquinone are 1,1,1,2-tetrachloroethane, 1,1,2,2-tetrachloroethane, nitrobenzene, chlorobenzene, 1,2- Dichlorobenzene, toluene or sulfone. These solvents can be used independently or in any combination with others. The sulfone is preferably tetramethylene sulfone. The reaction is preferably carried out at a temperature not exceeding 180 ° C. with stirring of the reaction mixture.
프리델-크라프트 반응 단계의 완료 뒤, DDA 조생성물로부터 알루미늄 함유 부생성물의 제거는 문제점을 야기하는데, 반응을 고상으로 수행할 때 특히 그러하다. 이 시점에서 알루미늄 함량의 감소는 공정의 후속 단계에서의 정제 사이클의 갯수를 감소시키기 때문에 중요하다. AQ4와 같은 차후의 세포 독성 생성물에의 잠재적 노출을 최소화할 수 있기 때문에 이는 중요한 고려사항이다.After completion of the Friedel-Crafts reaction step, the removal of aluminum-containing byproducts from the DDA crude product poses a problem, especially when the reaction is carried out in solid phase. Reducing the aluminum content at this point is important because it reduces the number of purification cycles in subsequent steps of the process. This is an important consideration because potential exposure to subsequent cytotoxic products such as AQ4 can be minimized.
상기 설명한 바와 같은 프리델-크라프트 반응을 수행한 뒤, DDA 조생성물을 오염시키는 알루미늄 함유 부생성물을 완전히 제거하거나 감량하는 것이 바람직하다.After performing the Friedel-Crafts reaction as described above, it is desirable to completely remove or reduce the aluminum containing byproducts that contaminate the DDA crude product.
알루미늄 함유 부생성물의 양을 감소시키는 바람직한 방법은 산 첨가에 의한 반응 용액과의 슬러리 형성이다. DDA 조생성물 내 알루미늄 함량의 감소는, 바람직하게는 염산 수용액으로 반응 용액을 몇 차례 슬러리시켜 달성된다.A preferred method of reducing the amount of aluminum containing byproducts is slurry formation with the reaction solution by acid addition. The reduction of the aluminum content in the DDA crude product is achieved by slurrying the reaction solution several times, preferably with aqueous hydrochloric acid.
슬러리 공정과 독립적으로 또는 그와 함께 이용할 수 있는 또 하나의 바람직한 방법은 킬레이트제의 반응 용액에의 첨가이다. 킬레이트제는 알루미늄 함유 불순물과의 알루미늄 착물을 형성하며, 이는 제거를 촉진시킨다. 적절한 킬레이트제의 선택은 용액으로부터의 침전, 상 이동 조건의 이용, 또는 기타 크기 배제 또는 여과 기술의 이용에 의한 알루미늄 착물의 제거를 가능케 한다.Another preferred method that can be used independently or in conjunction with the slurry process is the addition of the chelating agent to the reaction solution. Chelating agents form aluminum complexes with aluminum containing impurities, which promote removal. The selection of the appropriate chelating agent allows for the removal of the aluminum complex by precipitation from the solution, use of phase transfer conditions, or other size exclusion or use of filtration techniques.
AQ4의 형성Formation of AQ4
WO 00/05194A에 설명된 DDA로부터의 AQ4 합성은 중간 수준의 생성물 수율(~40%)을 보인다. 이 반응 단계는 0℃ 내지 100℃ 범위의 온도에서 수행한다. 이 반응 수행에 적합한 용매는 테트라하이드로퓨란, 콜리딘, 루티딘, 다이메틸폼아마이드, 다이메틸아세트아마이드, N-메틸피롤리돈, 다이메틸 설폭사이드, 다이글라임 및 설폴란이다. 이들 용매는 다른 것과의 임의의 조합으로 이용할 수도 있다.AQ4 synthesis from DDA described in WO 00 / 05194A shows moderate product yields (-40%). This reaction step is carried out at a temperature in the range of 0 ° C to 100 ° C. Suitable solvents for carrying out this reaction are tetrahydrofuran, collidine, lutidine, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, diglyme and sulfolane. These solvents may be used in any combination with other.
본 발명은 이 반응 단계에서 발생하는 산성 부생성물로부터의 AQ4의 분리에 관한 것이다. 산성 부생성물의 중화는 적합한 염기로 수행한다. 적합한 염기는 다이메틸 아미노피리딘, N-메틸 피페리딘, N-메틸 피롤리딘, 임의의 3차 아민, 임의의 수용성 3차 아민, 또는 고상 지지체에 결합된 임의의 이들 염기, 1족 알칼리 금속 탄산염 및 중탄산염이다. 바람직하게는, 수산화 암모늄/염수 냉각 수용액을 이용하여 반응의 산성 부생성물을 중화한다. 바람직하게는, AQ4의 워크업(workup)은 10℃ 내지 30℃ 범위의 온도에서 수행한다. 이 방법은 AQ4의 개선된 수율로 이어지며, 반응을 대규모로 수행하는 때에도 그러하다.The present invention relates to the separation of AQ4 from acidic byproducts arising in this reaction step. Neutralization of the acid byproducts is carried out with a suitable base. Suitable bases are dimethyl aminopyridine, N-methyl piperidine, N-methyl pyrrolidine, any tertiary amine, any water soluble tertiary amine, or any of these bases attached to a solid support, group 1 alkali metal Carbonates and bicarbonates. Preferably, the acid by-product of the reaction is neutralized with an aqueous ammonium hydroxide / brine cooling solution. Preferably, the workup of AQ4 is carried out at a temperature in the range of 10 ° C to 30 ° C. This method leads to improved yield of AQ4, even when the reaction is carried out on a large scale.
본 기술분야의 숙련된 자가 이해할 수 있듯이, 본 발명의 한 양태의 특징 및 바람직한 구체예는 본 발명의 다른 양태에도 관련된다.As will be appreciated by those skilled in the art, features and preferred embodiments of one aspect of the present invention also relate to other aspects of the present invention.
정의Justice
본 명세서에서 사용한 약학적으로 순수하다는 용어는 약제로서 사용하기에 충분히 순수한 화합물과 관련된다.As used herein, the term pharmaceutically pure refers to a compound that is pure enough to be used as a medicament.
본 명세서에서 사용한 옥사지리딘이라는 용어는 아래와 같이 C, N 및 O로 형성된 포화 3원 헤테로사이클 고리를 함유하는 작용기를 갖는 화합물과 관련된다.The term oxaziridine as used herein relates to a compound having a functional group containing a saturated three-membered heterocycle ring formed of C, N and O as follows.
특히 적합한 옥사지리딘은 2-벤젠-설포닐-3-페닐-옥사지리딘 및 하기에 도시된 것들이다.Particularly suitable oxaziridines are 2-benzene-sulfonyl-3-phenyl-oxaziridines and those shown below.
본 명세서에서 사용된 과산(peracid)이라는 용어는 -C(=O)OOH 작용기를 함유하는 화합물과 관련된다. 특히 적합한 과산은 m-클로로과벤조산, 과아세트산, 과벤조산, 트리플루오로과아세트산 및 3,5-다이나이트로퍼옥시벤조산을 포함한다.The term peracid, as used herein, relates to a compound containing a -C (= 0) OOH functional group. Particularly suitable peracids include m-chloroperbenzoic acid, peracetic acid, perbenzoic acid, trifluoroperacetic acid and 3,5-dynitroperoxybenzoic acid.
본 명세서에서 사용된 과산의 염이라는 용어는 하기에 정의된 적합한 양이온과 -C(=O)OO- 음이온성 작용기를 함유하는 화합물과 관련된다. 특히 적합한 과산의 염은 마그네슘 모노퍼옥시프탈레이트, 과아세트산 소듐 및 과아세트산 아연을 포함한다.The term salt of peracid, as used herein, relates to compounds containing suitable cations and -C (= 0) OO - anionic functional groups as defined below. Particularly suitable salts of peracids include magnesium monoperoxyphthalate, sodium peracetate and zinc peracetate.
본 명세서에서 사용된 지방족 알킬 알콜이라는 용어는 R-OH 형태의 화합물과 관련되며, 여기에서 R은 포화 선형 또는 분지형 알킬기이다. 본 명세서에서 사용된 알킬이라는 용어는 1 내지 7개의 탄소 원자를 갖는 포화 탄화수소 화합물로부터의 탄소 원자로부터 수소 원자를 제거함으로써 얻어지는 1가 부분(monovalent moiety)과 관련된다. 포화 선형 알킬기의 예는 메틸(C1), 에틸(C2), n-프로필(C3), n-부틸(C4), n-펜틸(아밀)(C5), n-헥실(C6), 및 n-헵틸(C7)을 포함하나 이에 한정되지는 않는다. 포화 분지형 알킬기의 예는 iso-프로필(C3), iso-부틸(C4), sec-부틸(C4), tert-부틸(C4), iso-펜틸(C5) 및 neo-펜틸(C5)를 포함한다. 특히 적합한 지방족 알킬 알콜은 메탄올, 에탄올, 프로판올 및 프로판-2-올을 포함한다.The term aliphatic alkyl alcohol as used herein relates to a compound in the form of R-OH, wherein R is a saturated linear or branched alkyl group. The term alkyl as used herein relates to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom from a saturated hydrocarbon compound having 1 to 7 carbon atoms. Examples of saturated linear alkyl groups are methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), n-butyl (C 4 ), n-pentyl (amyl) (C 5 ), n-hexyl (C 6 ), and n-heptyl (C 7 ). Examples of saturated branched alkyl groups are iso-propyl (C 3 ), iso-butyl (C 4 ), sec-butyl (C 4 ), tert-butyl (C 4 ), iso-pentyl (C 5 ) and neo-pentyl (C 5 ). Particularly suitable aliphatic alkyl alcohols include methanol, ethanol, propanol and propan-2-ol.
본 명세서에서 사용된 설폰이라는 용어는 C-S(=O)2-C 작용기를 함유하는 화합물과 관련된다. 특히 적합한 설폰은 테트라메틸렌 설폰이다.The term sulfone as used herein relates to a compound containing a CS (═O) 2 -C functional group. Particularly suitable sulfones are tetramethylene sulfones.
본 명세서에서 사용된 킬레이트제라는 용어는 둘 이상의 위치로부터 금속에 결합하는 화합물과 관련된다. 킬레이트 화합물 내 결합 원자는 선형 화합물의 일부 또는 환형 구조의 일부를 형성할 수 있다. 킬레이트제의 예는 에틸렌다이아민테트라아세트산 (EDTA), 에틸렌다이아민 (EDA) 및 다이에틸렌트리아민 (DETA), 및 이들의 음이온이다. 환형 킬레이트제의 예는 18-크라운-6 또는 15-크라운-5와 같은 크라운 에터, 크라이탠드(crytand), 스피어랜드(spherand) 또는 포피린이다.The term chelating agent, as used herein, relates to a compound that binds to a metal from two or more positions. The bonding atoms in the chelate compound may form part of the linear compound or part of the cyclic structure. Examples of chelating agents are ethylenediaminetetraacetic acid (EDTA), ethylenediamine (EDA) and diethylenetriamine (DETA), and their anions. Examples of cyclic chelating agents are crown ethers such as 18-crown-6 or 15-crown-5, crytand, spherand or porphyrin.
달리 언급하지 않는 한, 상기 설명한 것에는 이들 화합물의 주지된 이온, 염, 용매화물 및 보호된 형태가 포함된다.Unless stated otherwise, what is described above includes well-known ions, salts, solvates, and protected forms of these compounds.
예를 들어, 만일 화합물이 음이온이거나, 음이온일 수 있는 작용기를 갖는다면 (예컨대 -COOH는 -COO-일 수 있다), 적합한 양이온과 함께 염을 형성할 수 있다. 적합한 무기 양이온의 예는 Na+ 및 K+와 같은 알칼리 금속 이온, Ca2+ 및 Mg2+와 같은 알칼리 토금속 양이온, 및 Al3+와 같은 기타 양이온을 포함하나, 이에 한정되지는 않는다. 적합한 유기 양이온의 예는 암모늄 이온 (즉 NH4 +), 및 치환된 암모늄 이온 (예컨대 NH3R+, NH2R2 +, NHR3 +, NR4 +) 을 포함하나, 이에 한정되지는 않는다. 몇몇 적합한 치환된 암모늄 이온의 예는 다음에서 유도된 것들이다: 에틸아민, 다이에틸아민, 다이사이클로헥실아민, 트라이에틸아민, 부틸아민, 에틸렌다이아민, 에탄올아민, 다이에탄올아민, 피페라진, 벤질아민, 페닐벤질아민, 콜린, 메글루민 및 트로메타민은 물론, 리신 및 아르기닌과 같은 아미노산. 흔한 4차 암모늄 이온의 예는 N(CH3)4 +이다.For example, if the compound is anionic, or, if having a functional group which may be anionic (e.g. -COOH is -COO - may be), it can form salts with suitable cations. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth metal cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ . Examples of suitable organic cations include, but are not limited to, ammonium ions (ie NH 4 + ), and substituted ammonium ions (eg, NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ). . Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzyl Amino acids such as amines, phenylbenzylamine, choline, meglumine and tromethamine, as well as lysine and arginine. An example of a common quaternary ammonium ion is N (CH 3 ) 4 + .
만일 화합물이 양이온성이거나, 양이온일 수 있는 작용기를 갖고 있다면 (예컨대, -NH2는 -NH3 +일 수 있다), 적합한 음이온과 함께 염을 형성할 수 있다. 적합한 무기 음이온의 예는 다음 무기산으로부터 유도된 것들을 포함하나, 이에 한정되지는 않는다: 염산, 브롬산, 요오드산, 황산, 아황산, 질산, 아질산, 인산 및 아인산.If the compound is cationic or has a functional group that can be a cation (eg -NH 2 can be -NH 3 + ), it can form a salt with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric acid, bromic acid, iodic acid, sulfuric acid, sulfurous acid, nitric acid, nitrous acid, phosphoric acid and phosphorous acid.
적합한 유기 음이온의 예는 다음 유기산으로부터 유도된 것들을 포함하나, 이에 한정되지는 않는다: 2-아세톡시벤조산, 아세트산, 아스코르브산, 아스파르트산, 벤조산, 캠포설폰산, 신남산, 구연산, 에데트산, 에탄다이설폰산, 에탄설폰산, 푸마르산, 글루코헵톤산, 글루콘산, 글루탐산, 글라이콜산, 하이드록시말레산, 하이드록시나프탈렌 카복실산, 이세티온산, 젖산, 락토바이온산, 라우르산, 말레산, 말산, 메탄설폰산, 점액산(mucic acid), 올레산, 옥살산, 팔미트산, 파모산, 판토텐산, 페닐아세트산, 페닐설폰산, 프로피온산, 피루브산, 살리실산, 스테아르산, 호박산, 설파닐산, 타르타르산, 톨루엔설폰산 및 발레르산. 적합한 중합체 유기 음이온의 예는 다음 중합체 산으로부터 유도된 것들을 포함하나, 이에 한정되지는 않는다: 타닌산, 카복시메틸 셀룰로스.Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetoxybenzoic acid, acetic acid, ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, edetic acid, ethane Disulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxymaleic acid, hydroxynaphthalene carboxylic acid, isethionic acid, lactic acid, lactobionic acid, lauric acid, maleic acid, Malic acid, methanesulfonic acid, mucic acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pantothenic acid, phenylacetic acid, phenylsulfonic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanic acid, tartaric acid, toluene Sulfonic acid and valeric acid. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.
본 명세서에서 "용매화물"이라는 용어는 용질(예컨대 활성 화합물, 활성 화합물의 염)과 용매의 착물을 지칭하는 것으로 종래의 개념으로서 이용된다. 만일 용매가 물이라면, 용매화물은 수화물, 예컨대 일수화물, 이수화물, 삼수화물 등으로 편리하게 지칭할 수 있다.As used herein, the term “solvate” is used as a conventional concept to refer to a complex of a solute (such as the active compound, salt of the active compound) and a solvent. If the solvent is water, solvates may conveniently be referred to as hydrates such as monohydrate, dihydrate, trihydrate, and the like.
본 명세서에서 사용된 "전구약물"이라는 용어는 대사시에(예컨대, 생체 내) 원하는 활성 화합물을 생성하는 화합물과 관련된다. 전형적으로, 전구약물은 비활성이거나, 활성 화합물보다 덜 활성이지만, 유리한 취급, 투여 또는 대사 성질을 제공할 수 있다.As used herein, the term “prodrug” refers to a compound that produces the desired active compound upon metabolism (eg, in vivo). Typically, prodrugs are inactive or less active than the active compound, but can provide advantageous handling, administration, or metabolic properties.
합성 세부사항Composite details
DDA(6) 조생성물의 제조Preparation of DDA (6) Crude Product
DFPA 0.3kg (1.63mol), p-하이드로퀴논 0.2kg (1.82mol), 무수 AlCl3 분말 1.1kg (8.25mol) 및 테트라메틸렌 설폰 (1.8L)을 155℃ 내지 180℃의 온도에서 대략 12시간 동안 교반하였다. 그리고, 반응 혼합물을 얼음 냉각수(1.0L)로 급냉시키고 2M 염산 수용액(1.0L)으로 처리하였다. 현탁액을 여과하고, 고체 결과물을 진공하에 45℃에서 건조하였다. 건조 후 미세한 적색 분말(DDA 조생성물)을 얻었다. 이 반응을 같은 규모의 몇 개의 배치상에서 수행하여 68% 가량의 수율을 얻었다. 분리한 DDA는 알루미늄 함유 불순물로 오염되어 있었으며, 여기에서 분리한 생성물 내 알루미늄 함량은 표 1과 같이 3290ppm 내지 975ppm 범위였다.0.3 kg (1.63 mol) of DFPA, 0.2 kg (1.82 mol) of p-hydroquinone, 1.1 kg (8.25 mol) of anhydrous AlCl 3 powder, and tetramethylene sulfone (1.8 L) for approximately 12 hours at a temperature of 155 ° C to 180 ° C. Stirred. The reaction mixture was then quenched with ice cold water (1.0 L) and treated with 2M aqueous hydrochloric acid solution (1.0 L). The suspension is filtered and the solid result is dried at 45 ° C. under vacuum. After drying a fine red powder (DDA crude product) was obtained. This reaction was carried out on several batches of the same scale, yielding a yield of about 68%. The separated DDA was contaminated with aluminum-containing impurities, and the aluminum content in the separated product ranged from 3290 ppm to 975 ppm as shown in Table 1.
모든 배치들은 1몰 당량의 DDA로서 300g을 이용하였고, 다만 배치 5A의 경우는 200g을 이용하였다.All batches used 300 g as 1 molar equivalent of DDA except for 200 g for batch 5A.
생성물의 유기 성분은 HPLC를 이용하여 순수한 것으로 결정되었다.The organic component of the product was determined to be pure using HPLC.
DDA 조생성물의 정제Purification of DDA Crude Products
선행 방법을 이용하여 얻은 고체 DDA 조생성물을 2M 염산 수용액 (1.0L)으로 처리하여 슬러리를 형성하였다. 현탁액을 여과하여 고체를 분리하였다. 고체를 몇 차례 슬러리 및 여과한 뒤 고체를 진공하에서 45℃에서 건조하여 미세한 적색 분말을 얻었다. 이 단계의 질량 회수는 전형적으로 90%였다. 이 단계는 표 2와 같이 모든 배치에 대해 DDA 조생성물 내 알루미늄 함량의 감소를 가져왔다.The solid DDA crude product obtained using the previous method was treated with 2M aqueous hydrochloric acid solution (1.0 L) to form a slurry. The suspension was filtered to separate the solids. The solid was slurried and filtered several times and the solid was dried at 45 ° C. under vacuum to give a fine red powder. The mass recovery of this step is typically 90%. This step resulted in a reduction in the aluminum content in the DDA crude product for all batches as shown in Table 2.
생성물의 유기 성분은 HPLC를 이용하여 순수한 것으로 결정되었다.The organic component of the product was determined to be pure using HPLC.
AQ4의 제조 및 정제Preparation and Purification of AQ4
(AQ4는 WO 00/05194에 열거된 방법을 변형하여 제조하였다). 선행 단계에서 얻은 DDA 0.5kg (1.81mol), N,N-다이메틸에틸렌 다이아민 1.3L (12.08mol) 및 피리딘 (3.6L) 을 질소 분위기하에서 22시간 동안 40℃에서 교반하였다. 0℃로 냉각된 30% 수산화 암모늄 수용액/23% 염수의 용액 2L를 첨가하여 반응 혼합물을 워크업하였다. 슬러리 결과물을 3 내지 4시간 동안 0℃에서 교반하고 여과에 의해 청색 고체 생성물을 분리하였다. 이 고체를 10% 수산화 암모늄 수용액(1.0L)으로 세척하고 진공하에서 40℃ 내지 50℃에서 일정 무게가 될 때까지 건조하였다. 이 단계는 AQ4 540g (~73%) 가량을 꾸준히 생성하였다.(AQ4 was prepared by modifying the method listed in WO 00/05194). 0.5 kg (1.81 mol) of DDA, 1.3 L (12.08 mol) of N, N-dimethylethylene diamine and pyridine (3.6 L) obtained in the previous step were stirred at 40 ° C. for 22 hours under a nitrogen atmosphere. The reaction mixture was worked up by adding 2 L of a 30% aqueous ammonium hydroxide solution / 23% brine cooled to 0 ° C. The slurry result was stirred at 0 ° C. for 3-4 hours and the blue solid product was separated by filtration. The solid was washed with 10% aqueous ammonium hydroxide solution (1.0 L) and dried under vacuum to constant weight at 40 ° C to 50 ° C. This step consistently produced about 540 g (~ 73%) of AQ4.
위에서 얻은 정제된 DDA를 합친 뒤, 몇 개의 500g 배치로 나누어 이 단계에서 이용하였다.The purified DDAs obtained above were combined and then divided into several 500 g batches and used at this stage.
생성물의 순도를 HPLC를 이용하여 확인하였다.The purity of the product was confirmed using HPLC.
AQ4N의 합성Synthesis of AQ4N
마그네슘 모노퍼옥시프탈레이트 0.26kg (0.67mol)을 함유하는 메탄올 용액 (0.5L)을, 선행 단계로부터의 AQ4 0.2kg (0.48mol), 메탄올(0.8L) 및 다이클로로메탄(2.9L)의 약 -11℃로 냉각된 교반 용액에 한 방울씩 첨가하였다. 첨가를 완료한 뒤, 반응 용액이 0℃까지 승온하도록 둔 뒤 18시간 동안 교반하였다. 다음으로, 문헌의 절차를 이용하여 이 단계에서 AQ4N을 분리할 수 있다.Methanol solution (0.5 L) containing 0.26 kg (0.67 mol) of magnesium monoperoxyphthalate was prepared by adding 0.2 kg (0.48 mol) of AQ4 from the previous step, methanol (0.8 L) and dichloromethane (2.9 L). Dropwise was added to the stirred solution cooled to 11 ° C. After the addition was completed, the reaction solution was allowed to warm to 0 ° C. and stirred for 18 hours. Next, AQ4N can be separated at this stage using the procedure in the literature.
AQ4N의 이염산염(AQ4N.2HCl)의 제조 및 정제Preparation and Purification of AQ4N Dihydrochloride (AQ4N.2HCl)
에틸 아세테이트(4.0L)와 에탄올(0.8L)을 선행 단계로부터의 반응 용액과 같은 AQ4N 용액에 첨가하고, 용액 온도를 0℃로 유지하였다. 이 온도에서 1시간 동안 교반한 뒤, 교반한 용액을 약 -11℃로 냉각시키고 염화 아세틸 0.2L (2.8mol)를 한 방울씩 첨가하였다. 슬러리 결과물을 이 온도에서 10분 동안 교반한 뒤 반응 혼합물을 빠르게 여과하였다. 고체 조생성물을 얻고, 이를 에탄올과 물(2L)의 혼합물로 세척한 뒤, 무게가 일정할 때까지 진공하에서 건조하였다. 표 4와 같이, 양호한 순도의 AQ4N.2HCl 220g (~88%)을 전형적으로 얻었다. HPLC를 이용하여 생성물의 유기물 함량의 순도를 확인하였다.Ethyl acetate (4.0 L) and ethanol (0.8 L) were added to the same AQ4N solution as the reaction solution from the previous step and the solution temperature was maintained at 0 ° C. After stirring for 1 hour at this temperature, the stirred solution was cooled to about −11 ° C. and 0.2 L (2.8 mol) of acetyl chloride was added dropwise. The slurry result was stirred at this temperature for 10 minutes before the reaction mixture was filtered quickly. A solid crude product was obtained which was washed with a mixture of ethanol and water (2 L) and dried under vacuum until constant weight. As shown in Table 4, 220 g (˜88%) of AQ4N.2HCl with good purity were typically obtained. HPLC confirmed the purity of the organic content of the product.
약학적 순도를 위해, 위에서 얻은 생성물 100g을 추가 정제하였다. AQ4N.2HCl 조생성물을 물(0.6L)에 용해시키고 활성탄 (0.06kg)으로 처리하였다. 현탁액 결과물로부터 활성탄을 여과에 의해 제거하였다. 에탄올을 첨가(1.4L)하고 용액을 0℃로 냉각시켜 모액으로부터 생성물을 침전시켰다. 여과에 의해 침전을 분리하고 에탄올(4.0L)로 세척하였다. AQ4N.2HCl 생성물을 상온에서 진공하에 건조하였다. 이 단계의 질량 회수는 60% 가량이었다.For pharmaceutical purity, 100 g of the product obtained above was further purified. The crude AQ4N.2HCl product was dissolved in water (0.6 L) and treated with activated carbon (0.06 kg). Activated carbon was removed from the suspension result by filtration. Ethanol was added (1.4 L) and the solution cooled to 0 ° C. to precipitate the product from the mother liquor. The precipitate was separated by filtration and washed with ethanol (4.0 L). The AQ4N.2HCl product was dried under vacuum at room temperature. The mass recovery at this stage was about 60%.
HPLC는 생성물의 유기물 함량의 순도가 증가하였음을 보여 주었다.HPLC showed that the purity of the organic content of the product was increased.
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020067018670A KR20070031281A (en) | 2004-02-13 | 2005-02-11 | How to make A4N |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/544,778 | 2004-02-13 | ||
| KR1020067018670A KR20070031281A (en) | 2004-02-13 | 2005-02-11 | How to make A4N |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070031281A true KR20070031281A (en) | 2007-03-19 |
Family
ID=43655646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067018670A Withdrawn KR20070031281A (en) | 2004-02-13 | 2005-02-11 | How to make A4N |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20070031281A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200109953A (en) | 2019-03-15 | 2020-09-23 | 엘지전자 주식회사 | Cooing apparatus |
| KR20200111964A (en) | 2019-03-20 | 2020-10-05 | 엘지전자 주식회사 | Cooing apparatus |
-
2005
- 2005-02-11 KR KR1020067018670A patent/KR20070031281A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200109953A (en) | 2019-03-15 | 2020-09-23 | 엘지전자 주식회사 | Cooing apparatus |
| KR20200111964A (en) | 2019-03-20 | 2020-10-05 | 엘지전자 주식회사 | Cooing apparatus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9573922B2 (en) | Process-scale synthesis of urolithins | |
| EP3490988B1 (en) | New compound and process | |
| CN1046283C (en) | Method for preparing 9-aminocamptothecin | |
| WO2021190604A1 (en) | Preparation of cyclosporin derivatives | |
| JP2024009896A (en) | Method for producing prostaglandin analogs that donate nitric oxide | |
| AU2003241161B2 (en) | Esters in position 20 of camptothecins | |
| WO2002034712A1 (en) | Process for preparing substituted aromatic compounds and intermediates therefor | |
| CN102939298B (en) | Prepare the method for pteridine derivatives | |
| CN111315736B (en) | Method for preparing radNizole using acid addition salts | |
| KR20070031281A (en) | How to make A4N | |
| JP2007522194A (en) | Manufacturing method of AQ4N | |
| US20230128975A1 (en) | Process for the preparation of bromodomain inhibitor | |
| US6664421B2 (en) | Process for preparing zolpidem | |
| CN118388412A (en) | Method for preparing 6- (4-amino-2, 6-dichlorophenoxy) -4-isopropyl pyridazin-3 (2H) -ketone | |
| CA2445766A1 (en) | Improved process for preparing zolpidem | |
| MXPA06009058A (en) | Process for the preparation of aq4n | |
| US20050159596A1 (en) | Cyclic compounds and their use as complex ligands | |
| ES2283781T3 (en) | PROCEDURE TO PRODUCE A COMPOSITE OF 1,2,3-TRIAZOL. | |
| KR20250129627A (en) | Method for preparing nitrogen-containing fused ring compounds | |
| EP4626866A1 (en) | Novel trilaciclib intermediates, method of preparation and use thereof | |
| HK40002783A (en) | New compound and process | |
| HK40002783B (en) | New compound and process | |
| JPH04330045A (en) | Production of deacetylcolchicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060912 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20080313 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |